Zhijie Xu

6.8k total citations · 2 hit papers
208 papers, 4.7k citations indexed

About

Zhijie Xu is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhijie Xu has authored 208 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Molecular Biology, 72 papers in Cancer Research and 57 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhijie Xu's work include Ferroptosis and cancer prognosis (45 papers), RNA modifications and cancer (39 papers) and Cancer-related molecular mechanisms research (31 papers). Zhijie Xu is often cited by papers focused on Ferroptosis and cancer prognosis (45 papers), RNA modifications and cancer (39 papers) and Cancer-related molecular mechanisms research (31 papers). Zhijie Xu collaborates with scholars based in China, United States and United Kingdom. Zhijie Xu's co-authors include Yuanliang Yan, Zhicheng Gong, Shuangshuang Zeng, Long Qian, Lunquan Sun, Qiuju Liang, Bi Peng, Jie Wei, Shuang Dai and Yuan Cai and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Zhijie Xu

195 papers receiving 4.7k citations

Hit Papers

Exosome-based immunotherapy: a promising approach for can... 2020 2026 2022 2024 2020 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Exosome-based immunotherapy: a promising approach for cancer treatment
    2020 397 citations Zhijie Xu, Shuangshuang Zeng et al. profile →
  2. Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment
    2023 136 citations Qiaoli Yi, Zhijie Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhijie Xu China 37 3.1k 1.8k 871 729 564 208 4.7k
Yuanliang Yan China 35 2.5k 0.8× 1.5k 0.8× 730 0.8× 567 0.8× 504 0.9× 146 3.9k
Ke Cao China 34 2.9k 0.9× 1.9k 1.1× 1.0k 1.2× 1.2k 1.7× 761 1.3× 151 5.3k
Li Liu China 40 2.9k 0.9× 1.8k 1.0× 818 0.9× 1.1k 1.5× 593 1.1× 218 5.6k
Hanwen Zhang China 37 3.2k 1.0× 2.2k 1.2× 387 0.4× 691 0.9× 662 1.2× 143 5.0k
Li Li China 43 3.9k 1.2× 1.7k 0.9× 1.5k 1.7× 1.2k 1.6× 451 0.8× 262 6.3k
Chunhong Yan United States 38 3.0k 1.0× 1.4k 0.8× 791 0.9× 1.1k 1.5× 428 0.8× 106 4.8k
Shiwu Zhang China 39 2.8k 0.9× 1.5k 0.9× 668 0.8× 1.7k 2.3× 564 1.0× 169 4.7k
Xiangmin Tong China 27 1.9k 0.6× 1.3k 0.7× 909 1.0× 601 0.8× 279 0.5× 131 3.3k
Alexander T.H. Wu Taiwan 40 2.6k 0.8× 1.1k 0.6× 684 0.8× 1.1k 1.5× 484 0.9× 170 5.1k
Lin Zhao China 38 2.6k 0.8× 1.6k 0.9× 579 0.7× 926 1.3× 731 1.3× 148 4.3k

Countries citing papers authored by Zhijie Xu

Since Specialization
Citations

This map shows the geographic impact of Zhijie Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhijie Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhijie Xu more than expected).

Fields of papers citing papers by Zhijie Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhijie Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhijie Xu. The network helps show where Zhijie Xu may publish in the future.

Co-authorship network of co-authors of Zhijie Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhijie Xu. A scholar is included among the top collaborators of Zhijie Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhijie Xu. Zhijie Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Can, et al.. (2025). Tumor organoids in cancer medicine: from model systems to natural compound screening. Pharmaceutical Biology. 63(1). 89–109. 5 indexed citations
2.
Lu, Can, et al.. (2025). Nanozyme-Based Strategies in Cancer Immunotherapy: Overcoming Resistance to Enhance Therapeutic Efficacy. Aging and Disease. 0–0. 5 indexed citations
3.
4.
Xu, Zhijie, Tongfei Li, Qiaoli Yi, et al.. (2024). Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance. Drug Resistance Updates. 75. 101098–101098. 23 indexed citations
5.
Chen, Xi, Yuanliang Yan, Yuanhong Liu, Qiaoli Yi, & Zhijie Xu. (2024). Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer. Pharmaceutical Biology. 62(1). 394–403. 1 indexed citations
6.
7.
Li, Yun, Zhijie Xu, Xiaofeng Huang, et al.. (2024). Application of Carbon Nanomaterials to Enhancing Tumor Immunotherapy: Current Advances and Prospects. International Journal of Nanomedicine. Volume 19. 10899–10915. 7 indexed citations
8.
Peng, Bi, Jing Li, Yuanliang Yan, et al.. (2023). Non-coding RNAs: The recently accentuated molecules in the regulation of cell autophagy for ovarian cancer pathogenesis and therapeutic response. Frontiers in Pharmacology. 14. 1162045–1162045. 8 indexed citations
9.
Lu, Can, Xi Chen, Yuanliang Yan, et al.. (2022). Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma. Frontiers in Pharmacology. 13. 768743–768743. 8 indexed citations
10.
11.
Yan, Yuanliang, Yuan Cai, Qiuju Liang, et al.. (2022). Identification of m6A-Associated Gene DST as a Prognostic and Immune-Associated Biomarker in Breast Cancer Patients. SHILAP Revista de lepidopterología. 5 indexed citations
12.
Yi, Qiaoli, Jinwu Peng, Zhijie Xu, et al.. (2022). Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis. Frontiers in Bioengineering and Biotechnology. 10. 806851–806851. 9 indexed citations
13.
Xu, Zhijie, et al.. (2022). Whether the start time of elective lung surgery impacts perioperative outcomes and cost?. Frontiers in Surgery. 9. 922198–922198. 2 indexed citations
14.
Xu, Zhijie, Bi Peng, Qiuju Liang, et al.. (2021). Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma. Frontiers in Immunology. 12. 719175–719175. 133 indexed citations
15.
Xu, Zhijie, et al.. (2020). Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold. Journal of Cell Communication and Signaling. 14(1). 129–130. 2 indexed citations
16.
Yan, Yuanliang, Zhi Li, Shuangshuang Zeng, et al.. (2019). FGFR2-mediated phosphorylation of PTEN at tyrosine 240 contributes to the radioresistance of glioma. Journal of Cell Communication and Signaling. 13(3). 279–280. 13 indexed citations
17.
Zeng, Shuangshuang, Zhijie Xu, Xiang Wang, et al.. (2019). <p>Time series analysis of antibacterial usage and bacterial resistance in China: observations from a tertiary hospital from 2014 to 2018</p>. Infection and Drug Resistance. Volume 12. 2683–2691. 20 indexed citations
18.
Xu, Zhijie, Yuanliang Yan, Long Qian, & Zhicheng Gong. (2017). Long non-coding RNAs act as regulators of cell autophagy in diseases. Oncology Reports. 37(3). 1359–1366. 51 indexed citations
19.
Ma, Xiaoqian, Zhijie Xu, Lifang Yang, et al.. (2013). EBV-LMP1-targeted DNAzyme induces DNA damage and causes cell cycle arrest in LMP1-positive nasopharyngeal carcinoma cells. International Journal of Oncology. 43(5). 1541–1548. 15 indexed citations
20.
Wang, Meng, Jie Yang, Zhijie Xu, & Kuo‐Chen Chou. (2004). SLLE for predicting membrane protein types. Journal of Theoretical Biology. 232(1). 7–15. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuanliang Yan Breakdown of academic impact, for papers by Ke Cao Breakdown of academic impact, for papers by Li Liu Breakdown of academic impact, for papers by Hanwen Zhang Breakdown of academic impact, for papers by Li Li Breakdown of academic impact, for papers by Chunhong Yan Breakdown of academic impact, for papers by Shiwu Zhang Breakdown of academic impact, for papers by Xiangmin Tong Breakdown of academic impact, for papers by Alexander T.H. Wu Breakdown of academic impact, for papers by Lin Zhao
Rankless by CCL
2026